JGC
PTCT icon

J. Goldman & Co’s PTC Therapeutics PTCT Stock Holding History

J. Goldman & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,700
Closed -$94K – 418
2017
Q3 		$94K Sell
4,700
-195,000
-98% -$3.82M ﹤0.01% 319
2017
Q2 		$3.66M Sell
199,700
-30,300
-13% -$408K 0.2% 128
2017
Q1 		$2.26M Buy
+230,000
New +$2.78M 0.11% 198

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Goldman & Co's PTCT Position: Q4 2025 in Review

J. Goldman & Co sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 7,816 shares — an estimated $480K sold.

J. Goldman & Co first reported a position in PTCT in Q1 2015 and held it in 8 quarters. The position peaked at $12.4M in Q1 2017. 351 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • J. Goldman & Co reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 7,816 PTC Therapeutics shares in Q4 2025, an estimated $480K.
  • J. Goldman & Co first reported a position in PTC Therapeutics in Q1 2015 and held it in 8 quarters.
  • J. Goldman & Co's PTC Therapeutics position peaked at $12.4M in Q1 2017.
  • 351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.